Bank of America Securities analyst Craig Bijou reiterated a Buy rating on SI-Bone (SIBN – Research Report) today and set a price target of $21.00. Craig Bijou has given his Buy rating due to a ...

SI-BONE, Inc., a company focused on medical technologies for sacropelvic disorders, announced it will release its financial results for the fourth quarter and full year of 2024 on February 24, 2025, ...

SI-BONE reports strong revenue growth and improved financial metrics for Q4 2024 and FY 2024, achieving positive adjusted EBITDA. SI-BONE, Inc. reported strong financial results for the fourth quarter ...

The medical device maker posted a satisfying beat-and-raise third quarter. During the period, it managed to narrow its net loss considerably. SI-Bone took the wraps off its third-quarter numbers just ...

Today, we take a look at SI-BONE, Inc., a medical device company focused on developing implantable devices for musculoskeletal disorders. The company is targeting a large potential market, delivers ...

SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be ...

Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed hospital inpatient rule for New Technology Add-On Payment (“NTAP”) effective ...

SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be ...

Canaccord Genuity analyst Caitlin Cronin maintained a Buy rating on SI-Bone today and set a price target of $27.00. According to TipRanks, Cronin is a 4-star analyst with an average return of 15.7% ...

Si-Bone makes the iFuse Implant System for the sacroiliac joint, found in the lower back. The company said it increased its surgeon base to 950 surgeons in the U.S. Revenue for Si-Bone was up 46% year ...